Main Pharmacological Strategies Against SARS-CoV-2
There are currently no specific drugs for COVID-19. However, several drugs approved for other situations, as well as several investigative agents, are being studied for the treatment of COVID-19 in several hundred clinical trials worldwide. In anticipation of the results of clinical trials, differen...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bucharest College of Physicians
2020-09-01
|
| Series: | Modern Medicine |
| Subjects: | |
| Online Access: | https://medicinamoderna.ro/wp-content/uploads/2020/09/RMM_art-3.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850145156347461632 |
|---|---|
| author | Thais Gonçalves Fontes Afrânio Côgo Destefani |
| author_facet | Thais Gonçalves Fontes Afrânio Côgo Destefani |
| author_sort | Thais Gonçalves Fontes |
| collection | DOAJ |
| description | There are currently no specific drugs for COVID-19. However, several drugs approved for other situations, as well as several investigative agents, are being studied for the treatment of COVID-19 in several hundred clinical trials worldwide. In anticipation of the results of clinical trials, different medical actors around the world have used drugs empirically and with unknown safety profiles. It should be noted that emerging data demonstrated that cardiovascular comorbidities are very common in patients with COVID-19 and that these patients are at increased risk of death. To trace a path of light through the cloudiness that we live on COVID 19, we conducted a bibliographic search, aiming, mostly, to present concise, relevant and scientific information. The main groups of drugs and their adverse effects and drug interactions were raised. Specific concerns in patients with COVID-19 include underlying structural heart disease, cardiac injury, kidney and liver dysfunction, limited resources for cardiac monitoring and drug interaction. Clear administration protocols must be in place in all hospitals and clinics that use drugs for the treatment of COVID-19, to assist in research and analysis of possible drugs capable of inhibiting the virus without consequent complications. |
| format | Article |
| id | doaj-art-e46a71e4765448879995ca5c6e349d0a |
| institution | OA Journals |
| issn | 1223-0472 2360-2473 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | Bucharest College of Physicians |
| record_format | Article |
| series | Modern Medicine |
| spelling | doaj-art-e46a71e4765448879995ca5c6e349d0a2025-08-20T02:28:10ZengBucharest College of PhysiciansModern Medicine1223-04722360-24732020-09-01273153157https://doi.org/10.31689/rmm.2020.27.3.153Main Pharmacological Strategies Against SARS-CoV-2Thais Gonçalves Fontes0Afrânio Côgo Destefani1Faculty of Biomedical Sciences, Espírito Santo, Cariacica, BrasilFaculty of Biomedical Sciences, Espírito Santo, Cariacica, BrasilThere are currently no specific drugs for COVID-19. However, several drugs approved for other situations, as well as several investigative agents, are being studied for the treatment of COVID-19 in several hundred clinical trials worldwide. In anticipation of the results of clinical trials, different medical actors around the world have used drugs empirically and with unknown safety profiles. It should be noted that emerging data demonstrated that cardiovascular comorbidities are very common in patients with COVID-19 and that these patients are at increased risk of death. To trace a path of light through the cloudiness that we live on COVID 19, we conducted a bibliographic search, aiming, mostly, to present concise, relevant and scientific information. The main groups of drugs and their adverse effects and drug interactions were raised. Specific concerns in patients with COVID-19 include underlying structural heart disease, cardiac injury, kidney and liver dysfunction, limited resources for cardiac monitoring and drug interaction. Clear administration protocols must be in place in all hospitals and clinics that use drugs for the treatment of COVID-19, to assist in research and analysis of possible drugs capable of inhibiting the virus without consequent complications.https://medicinamoderna.ro/wp-content/uploads/2020/09/RMM_art-3.pdfcovid-19sars-cov-2strategy |
| spellingShingle | Thais Gonçalves Fontes Afrânio Côgo Destefani Main Pharmacological Strategies Against SARS-CoV-2 Modern Medicine covid-19 sars-cov-2 strategy |
| title | Main Pharmacological Strategies Against SARS-CoV-2 |
| title_full | Main Pharmacological Strategies Against SARS-CoV-2 |
| title_fullStr | Main Pharmacological Strategies Against SARS-CoV-2 |
| title_full_unstemmed | Main Pharmacological Strategies Against SARS-CoV-2 |
| title_short | Main Pharmacological Strategies Against SARS-CoV-2 |
| title_sort | main pharmacological strategies against sars cov 2 |
| topic | covid-19 sars-cov-2 strategy |
| url | https://medicinamoderna.ro/wp-content/uploads/2020/09/RMM_art-3.pdf |
| work_keys_str_mv | AT thaisgoncalvesfontes mainpharmacologicalstrategiesagainstsarscov2 AT afraniocogodestefani mainpharmacologicalstrategiesagainstsarscov2 |